Whole-genome sequencing was better at identifying nosocomial influenza A outbreak clusters than hemagglutinin (HA)/neuraminidase (NA) gene sequencing.
A significant number of asymptomatic people shed the influenza virus.
Data supporting the selection of the antiviral conjugate CB-012 as Cidara Therapeutics Incorporated’s first clinical development candidate from the company’s influenza program.
The NIH has announced the initiation of a phase 1 clinical trial assessing the safety, tolerability, and efficacy of a “universal” influenza vaccine candidate, H1ssF_3928, in healthy adult patients.
Influenza activity was linked to increased heart failure hospitalizations in 4 influenza seasons.
In children aged 6–35 months, vaccination with 2 doses of IIV4 can protect against influenza and reduces the frequency of severe outcomes.
Adults who received the flu vaccine in 2017 to 2018 had higher antibody titers against the egg-adapted vaccine and lower titers against circulating virus.
Influenza vaccine efficacy, between November 23, 2018 and February 2, 2019, was 47% overall and 61% for young children.